Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of izokibep (ABY-035) in moderate-to-severe plaque psoriasis
2017-001615-36Phase 2Completed
- Sponsor
- Affibody Medical AB
- Start
- Sep 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of izokibep in plaque psoriasis (4 arms), sponsored by Affibody Medical AB. Primary endpoint: PASI 90 response at week 12. Started Sep 2017; status: completed.
02
Drugs
izokibep
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2017-001615-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001615-36.